Torrey Pines Therapeutics Sells Alzheimer’s Program to Partner


TorreyPines Therapeutics (NASDAQ:TPTX) says it has agreed to sell its Alzheimer’s disease genetics research program for $1.5 million to partner Eisai Co. TorreyPines will record the payment from the Nov. 6 deal in its fourth quarter financial results, the company said today in a filng with government regulators. 

Bruce V. Bigelow is the editor of Xconomy San Diego. You can e-mail him at or call (619) 669-8788 Follow @

By posting a comment, you agree to our terms and conditions.